Table 1.
Baseline Clinical Characteristics by Treatment Modality and Renal Function
| PCI | CABG | |||||
|---|---|---|---|---|---|---|
| AKI N=79 | No AKI N=789 | P-value | AKI N=129 | No AKI N=695 | P-value | |
| Age (± SD) | 64.2±9.5 | 63.0±8.9 | 0.24 | 64.5±8.8 | 62.5±9.0 | 0.02 |
| Male Gender, n (%) | 57 (72.2) | 574 (72.8) | 0.90 | 93 (72.1) | 480 (69.1) | 0.53 |
| BMI (± SD) | 30.4±6.4 | 29.5±5.2 | 0.25 | 30.6±5.8 | 29.7±5.2 | 0.07 |
| Current Smoker, n (%) | 11 (13.9) | 112 (14.2) | >0.99 | 20 (15.5) | 119 (17.1) | 0.70 |
| Hypertension, n (%) | 66 (83.5) | 663 (84.0) | 0.87 | 117 (90.7) | 584 (84.0) | 0.06 |
| Dyslipidemia, n (%) | 63 (79.7) | 666 (84.4) | 0.26 | 104 (80.6) | 589 (84.7) | 0.24 |
| History of myocardial infarction, n (%) | 26 (32.9) | 196 (24.8) | 0.14 | 35 (27.1) | 178 (25.6) | 0.74 |
| PVD, n (%) | 12 (15.2) | 77 (9.8) | 0.17 | 20 (15.5) | 63 (9.1) | 0.04 |
| Type of diabetes (Type 1) | 8 (10.1) | 25 (3.2) | 0.01 | 7 (5.4) | 28 (4.0) | 0.48 |
| CKD | 26 (32.9) | 182 (23.1) | 0.05 | 50 (38.8) | 158 (22.7) | 0.0002 |
| Admission Medications | ||||||
| Aspirin, n (%) | 73 (92.4) | 718 (91.0) | 0.84 | 119 (92.2) | 627 (90.2) | 0.62 |
| Beta-blockers, n (%) | 58 (73.4) | 601 (76.2) | 0.58 | 99 (76.7) | 519 (74.7) | 0.66 |
| Statins, n (%) | 60 (75.9) | 656 (83.1) | 0.12 | 100 (77.5) | 586 (84.3) | 0.07 |
| Clopidogrel, n (%) | 14 (17.7) | 214 (27.1) | 0.08 | 38 (29.5) | 131 (18.8) | 0.01 |
| Insulin, n (%) | 37 (46.8) | 259 (32.8) | 0.02 | 57 (44.2) | 198 (28.5) | <0.001 |
| Anticoagulants, n (%) | 9 (11.4) | 131 (16.6) | 0.26 | 24 (18.6) | 99 (14.2) | 0.23 |
| Nitrates, n (%) | 31 (39.2) | 317 (40.2) | 0.90 | 53 (41.1) | 258 (37.1) | 0.43 |
| ACEI/ARB, n (%) | 54 (68.4) | 512 (64.9) | 0.62 | 86 (66.7) | 448 (64.5) | 0.69 |
| Laboratory results | ||||||
| Glycated Hemoglobin (g/l) | 8.0±1.6 | 7.7±1.8 | 0.17 | 7.6±1.4 | 7.7±1.7 | 0.25 |
| eGFR (ml/min/1.73m2) | 71.8±28.0 | 76.3±20.5 | 0.17 | 68.5±24.0 | 76.1±19.4 | <0.001 |
| LVEF | 57.3±11.9 | 58.4±11.5 | 0.43 | 58.5±13.6 | 58.9±11.1 | 0.70 |
| Clinical Presentation | ||||||
| STEMI, n (%) | 3 (3.8) | 57 (7.2) | 0.35 | 7 (5.4) | 41 (5.9) | >0.99 |
| NSTEMI, n (%) | 13 (16.5) | 202 (25.6) | 0.08 | 33 (25.6) | 168 (24.2) | 0.74 |
| Stable angina, n (%) | 63 (79.7) | 530 (67.2) | 0.02 | 89 (69.0) | 486 (69.9) | 0.84 |
BMI- Body Mass Index, PCI- percutaneous coronary intervention, CABG- coronary artery bypass grafting, STEMI – ST elevation myocardial infarction, TIA- transient ischemic attack, PVD- peripheral vascular disease, ACEI- Angiotensin converting enzyme inhibitors; ARB - Angiotensin receptor blocker, CTO- chronic total occlusion